fbpx

WHO Raises Alert On ‘Contaminated’ Cough Syrups As 66 Children Die

Following the death of 66 children in Gambia, the World Health Organisation (WHO), has issued an alert on four cough syrups made by India-based Maiden Pharmaceuticals.

The four products are listed as “Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup”.

Speaking on Wednesday at a briefing on global health issues, WHO Director-General, Tedros Ghebreyesus, said the “contaminated medicines”, which were identified in Gambia, were “linked with acute kidney injuries and 66 deaths among children” in the country.

Adding that the WHO is conducting further investigations with the suspected companies and regulatory authorities in India.

So far, laboratory research on the drugs have proven that the drugs are toxic to the human body as they contain unacceptable volume of unsafe mixtures especially for children.

In a statement issuing the alert, the WHO said the four products have been identified in Gambia, but may have been distributed through informal markets to other countries or regions.

“Laboratory analysis of samples of each of the four products confirms that they contain unacceptable amounts of diethylene glycol and ethylene glycol as contaminants. Diethylene glycol and ethylene glycol are toxic to humans when consumed and can prove fatal,” the statement reads.

“Toxic effects can include abdominal pain, vomiting, diarrhoea, inability to pass urine, headache, altered mental state, and acute kidney injury which may lead to death.

See also: Doctor Found Drunk As Four New-borns Die In Delta

“All batches of these products should be considered unsafe until they can be analyzed by the relevant National Regulatory Authorities.

“The substandard products referenced in this alert are unsafe and their use, especially in children, may result in serious injury or death. It is important to detect and remove these substandard products from circulation to prevent harm to patients.”

They therefore called on the entire supply chains accross the world and in extention, the public to be vigilant against such drugs and report to the respective authority when seen.

“WHO requests increased surveillance and diligence within the supply chains of countries and regions likely to be affected by these products. Increased surveillance of the informal/unregulated market is also advised.

“If you have these substandard products, please DO NOT use them. If you, or someone you know, have used these products or suffered any adverse reaction/event after use, you are advised to seek immediate medical advice from a qualified healthcare professional and report the incident to the National Regulatory Authority or National Pharmacovigilance Centre.”

Source: India Today

Clare Ijeoma

Leave a Reply

Your email address will not be published. Required fields are marked *